Patents by Inventor Barry A. Morgan

Barry A. Morgan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Patent number: 7157420
    Abstract: The present invention provides methods of treating an autoimmune disorder (e.g., lupus erythematosus, multiple sclerosis, myasthenia gravis, vasculitis and diabetes mellitus) in a subject by administering to the subject a therapeutically effective amount of one or more compounds of the invention.
    Type: Grant
    Filed: October 8, 2004
    Date of Patent: January 2, 2007
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles M. Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
  • Somatostatin agonists
    Patent number: 7144859
    Abstract: The present invention is directed to cyclic peptides of formula (I): X-A1-cyclo(D-Cys-A3-A4-Lys-A6-A7)-A8-Y, or a pharmaceutically acceptable salt thereof. The peptides bind selectively to the somatostatin subtype receptor type-5 and elicit an agonist effect from the somatostatin subtype receptors.
    Type: Grant
    Filed: January 4, 2005
    Date of Patent: December 5, 2006
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques SAS
    Inventors: Dean Sadat-Aalaee, Barry A. Morgan
  • Farnesyl transferase inhibitors
    Publication number: 20060252760
    Abstract: A family of compounds capable of inhibiting the activity of farnesyl transferase.
    Type: Application
    Filed: May 30, 2006
    Publication date: November 9, 2006
    Inventors: Thomas Gordon, Barry Morgan
  • Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
    Publication number: 20060223866
    Abstract: The present invention relates to compounds which modulate the activity of the S1P1 receptor, the use of these compounds for treating conditions associated with signaling through the S1P1 receptor, and pharmaceutical compositions comprising these compounds.
    Type: Application
    Filed: February 6, 2006
    Publication date: October 5, 2006
    Applicant: Praecis Pharmaceuticals, Inc.
    Inventors: Ghotas Evindar, Hongfeng Deng, Barry Morgan
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Publication number: 20060223758
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Application
    Filed: March 24, 2006
    Publication date: October 5, 2006
    Applicant: Praecis Pharmaceuticals, Inc.
    Inventors: Gary Olson, Christopher Self, Lily Lee, Charles Cook, Jens Birktoft, Barry Morgan, Christopher Arico-Muendel
  • Methionine aminopeptidase-2 inhibitors and methods of use thereof
    Patent number: 7105482
    Abstract: The present invention provides methods of treating, parasitic infections, thymoma, and lymphoid malignancies in a subject by administering to the subject a therapeutically effective amount of one or more of the compounds of the invention.
    Type: Grant
    Filed: May 2, 2003
    Date of Patent: September 12, 2006
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
  • Somatostatin analog and uses thereof
    Patent number: 7094753
    Abstract: Claimed is a somatostatin agonist according to formula (I), D-Phe-c(Cys-Tyr(I)-D-Trp-Lys-Val-Cys)-Thr-NH2, ??(I) or a pharmaceutically acceptable salt thereof, and uses thereof.
    Type: Grant
    Filed: November 21, 2002
    Date of Patent: August 22, 2006
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques, SAS
    Inventors: Thomas D. Gordon, Barry A. Morgan, Michael D. Culler
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Patent number: 7084108
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Grant
    Filed: November 1, 2001
    Date of Patent: August 1, 2006
    Assignee: Praecis Pharmaceuticals, Inc.
    Inventors: Gary L. Olson, Christopher Self, Lily Lee, Charles Michael Cook, Jens Birktoft, Barry Morgan, Christopher C. Arico-Muendel
  • Prenyl transferase inhibitors
    Patent number: 7084135
    Abstract: A family of imidazole compounds useful for inhibiting the activity of prenyl transferases.
    Type: Grant
    Filed: December 30, 1999
    Date of Patent: August 1, 2006
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques, SAS
    Inventors: Thomas D. Gordon, Barry A. Morgan
  • Prenyl transferase inhibitors
    Publication number: 20060142275
    Abstract: A family of imidazole compounds useful for inhibiting the activity of prenyl transferases. The compounds are covered by the following formula: wherein X is (CHR11)n3(CH2)n4Z(CH2)n5 where Z is O, N(R12), S, or a bond; Y is CO, CH2, CS, or a bond; R1 is or N(R24R25); and the remaining substituents are as defined in the disclosure.
    Type: Application
    Filed: February 14, 2006
    Publication date: June 29, 2006
    Inventors: Thomas Gordon, Barry Morgan
  • Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
    Publication number: 20060135786
    Abstract: The present invention relates to compounds which modulate the activity of the S1P1 receptor, the use of these compounds for treating conditions associated with signaling through the S1P1 receptor, and pharmaceutical compositions comprising these compounds.
    Type: Application
    Filed: August 12, 2005
    Publication date: June 22, 2006
    Applicant: Praecis Phamaceuticals, Inc.
    Inventors: Ashis Saha, Malcolm Kavarana, Ghotas Evindar, Alexander Satz, Barry Morgan
  • Product inhibiting transduction of G heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment
    Patent number: 7034024
    Abstract: The invention concerns a product inhibiting transduction of G heterotrimeric protein signals combined with another anti-cancer agent, in particular farnesyltransferase inhibitors, taxol or gemcitabin, for simultaneous, separate or prolonged therapeutic use in cancer treatment.
    Type: Grant
    Filed: November 8, 2000
    Date of Patent: April 25, 2006
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)
    Inventors: Grégoire Prevost, Marie-Odile Lonchampt, Thomas Gordon, Barry Morgan
  • Farnesyl transferase inhibitors
    Publication number: 20060079530
    Abstract: A family of compounds capable of inhibiting the activity of farnesyl transferase.
    Type: Application
    Filed: November 28, 2005
    Publication date: April 13, 2006
    Inventors: Thomas Gordon, Barry Morgan
  • Product comprising a transduction inhibitor of heterotrimeric G protein signals combined with another anti-cancer agent for therapeutic use in the treatment of cancer
    Publication number: 20060074078
    Abstract: A composition for treating cancer comprising an anti-tumorally effective amount of a product comprising at least one transduction inhibitor of heterotrimeric G protein signals and at least one other anti-cancer agent selected from the group consisting of prenyltransferase inhibitors, taxol and its analogues, gemcitabine and camptothecin and its analogues, administered simultaneously, separately or spread over a period of time and a pharmaceutical carrier.
    Type: Application
    Filed: November 10, 2005
    Publication date: April 6, 2006
    Inventors: Gregoire Prevost, Marie-Odile Lonchampt, Thomas Gordon, Barry Morgan
  • Farnesyl transferase inhibitors
    Patent number: 7022704
    Abstract: A family of tetrahydroimidazo[1,2a]pyrazine based compounds capable of inhibiting the activity of farnesyl transferase and treating tumors and restenosis having the following structure: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in the specification.
    Type: Grant
    Filed: October 18, 2002
    Date of Patent: April 4, 2006
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques, S.A.S.
    Inventors: Thomas D. Gordon, Barry A. Morgan
  • Somatostatin analog and uses thereof
    Publication number: 20060069017
    Abstract: Claimed is a somatostatin agonist according to formula (I), D-Phe-c(Cys-Tyr(I)-D-Trp-Lys-Val-Cys)-Thr-NH2,??(I) or a pharmaceutically acceptable salt thereof, and uses thereof.
    Type: Application
    Filed: November 8, 2005
    Publication date: March 30, 2006
    Inventors: Thomas Gordon, Barry Morgan, Michael Culler
  • Somatostatin agonists
    Publication number: 20050164922
    Abstract: The present invention is directed to cyclic peptides of formula (I): X-A1-cyclo(D-Cys-A3-A4-Lys-A6-A7)-A8-Y, or a pharmaceutically acceptable salt thereof. The peptides bind selectively to the somatostatin subtype receptor type-5 and elicit an agonist effect from the somatostatin subtype receptors.
    Type: Application
    Filed: January 4, 2005
    Publication date: July 28, 2005
    Inventors: Dean Sadat-Aalaee, Barry Morgan
  • Methods for synthesis of encoded libraries
    Publication number: 20050158765
    Abstract: The present invention provides a method of synthesizing libraries of molecules which include an encoding oligonucleotide tag.
    Type: Application
    Filed: December 17, 2004
    Publication date: July 21, 2005
    Applicant: Praecis Pharmaceuticals, Inc.
    Inventors: Barry Morgan, Stephen Hale, Christopher Arico-Muendel, Matthew Clark, Richard Wagner, David Israel, Malcolm Gefter, Dennis Benjamin, Nils Hansen, Malcolm Kavarana, Steffen Creaser, George Franklin, Paolo Centrella, Raksha Acharya
  • Therapeutic agents and methods of use thereof for the modulation of angiogenesis
    Publication number: 20050130903
    Abstract: The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
    Type: Application
    Filed: October 8, 2004
    Publication date: June 16, 2005
    Inventors: Gary Olson, Christopher Self, Lily Lee, Charles Cook, Jens Birktoft, Barry Morgan, Christopher Arico-Muendel
  • Neuromedin b and somatostatin receptor agonists
    Patent number: 6903074
    Abstract: A novel class of analogs which exhibit both high affinity and selectivity for Neuromedin B and Somatostann receptors are claimed. One example is Nal-Tyr-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH2.
    Type: Grant
    Filed: June 5, 2000
    Date of Patent: June 7, 2005
    Assignee: Societe de Conseils de Recherches et d'Applications Scientifiques, S.A.S.
    Inventors: Barry A. Morgan, Dean Sadat-Aalaee